Celltrion Inc. announced that its cancer treatment “Herzuma” (trastuzumab) has secured a supply deal with the Brazilian federal government for the fifth year in a row. The deal ensures that Celltrion will provide 660,000 vials of the drug, used for breast and stomach cancer, through its local subsidiary until 2025.
Celltrion attributed its success in securing the contract to its well-established supply chain and local presence in Brazil. In addition to Herzuma, the company will supply an additional 90,000 vials of its autoimmune disease drug “Remsima” (infliximab) following a special request from the government.
Looking ahead, Celltrion aims to strengthen its position in the Brazilian market with follow-up products like Vegzelma, slated for launch later this year. The deal reinforces the company’s strategy to expand its presence in Latin America.
